XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,527,397 | -7.3% | 44,713 | +4.5% | 0.00% | 0.0% |
| Q2 2023 | $1,647,492 | -3.0% | 42,792 | -9.9% | 0.00% | 0.0% |
| Q1 2023 | $1,699,131 | +177.5% | 47,475 | +205.7% | 0.00% | – |
| Q4 2022 | $612,268 | +46.5% | 15,528 | +34.1% | 0.00% | – |
| Q3 2022 | $418,000 | +21.9% | 11,578 | +2.7% | 0.00% | – |
| Q2 2022 | $343,000 | +3.9% | 11,273 | +4.7% | 0.00% | – |
| Q1 2022 | $330,000 | +0.6% | 10,771 | +2.5% | 0.00% | – |
| Q4 2021 | $328,000 | +218.4% | 10,513 | +55.8% | 0.00% | – |
| Q3 2021 | $103,000 | +368.2% | 6,748 | +464.2% | 0.00% | – |
| Q2 2021 | $22,000 | +4.8% | 1,196 | 0.0% | 0.00% | – |
| Q1 2021 | $21,000 | +16.7% | 1,196 | 0.0% | 0.00% | – |
| Q4 2020 | $18,000 | +38.5% | 1,196 | 0.0% | 0.00% | – |
| Q3 2020 | $13,000 | -13.3% | 1,196 | 0.0% | 0.00% | – |
| Q2 2020 | $15,000 | – | 1,196 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |